Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) has provided an update.
CANbridge Pharmaceuticals has disclosed that, following completion of a recent share subscription, the subscriber has become a substantial shareholder and connected person under Hong Kong listing rules, bringing affiliate WuXi Biologics Licensor into connected-person status as well. As a result, existing exclusive license agreements between CANbridge CARE Pharma and WuXi Biologics Licensor covering four biologic programs, CAN103, CAN104, CAN105 and CAN106, are now classified as continuing connected transactions, triggering ongoing disclosure, annual review and, where applicable, shareholder approval requirements under Chapter 14A of the Listing Rules.
The reclassification does not alter the underlying commercial arrangements but formalizes additional governance and transparency obligations for CANbridge, underscoring regulatory scrutiny of related-party transactions in the Hong Kong market. For investors and stakeholders, the move clarifies the compliance framework around key licensed assets, potentially supporting confidence in the company’s handling of collaborations with a major shareholder’s affiliate while preserving continuity in its rare-disease and biologics development pipeline.
The most recent analyst rating on (HK:1228) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical industry with a focus on innovative therapeutics. Through its subsidiary CANbridge CARE Pharma, the company engages in licensing and developing biologic drugs, including enzyme replacement and antibody-based therapies, for specialized and rare disease markets.
Average Trading Volume: 3,778,457
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.27B
For detailed information about 1228 stock, go to TipRanks’ Stock Analysis page.